Elan's $375 mil. acquisition of Sano brings two Phase III transdermal projects.
Executive Summary
ELAN ACQUISITION OF SANO BRINGS TWO PHASE III TRANSDERMAL PROJECTS to Elan's development portfolio, the company said Dec. 15. Sano's highest profile project is a transdermal formulation of Bristol-Myers Squibb's anxiolytic BuSpar (buspirone), and the company also has a smoking cessation patch in Phase III.
You may also be interested in...
Aveva Eyeing Hypertension, Pain Relief Categories For Transdermal Therapies
A generic clonidine patch will be Aveva Drug Delivery Systems' first product launch following the company's divestiture by Elan
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011